Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock

Background Despite the availability of potent antibiotics and intensive care, mortality rates from septic shock are 40–70%. We assessed the safety and efficacy of murine monoclonal antibody to human tumour necrosis factor α (TNF α MAb) in the treatment of septic shock. Methods In a randomised, multicentre, double-blind, placebo-controlled clinical trial in 105 hospitals in the USA and Canada, we randomly assigned 1879 patients a single infusion of 7•5 mg/kg TNFα MAb (n=949) or placebo (0•25% human serum albumin n=930). Our main outcome measurement was the rate of all-cause mortality at 28 days. Findings 382 (40•3%) of 948 patients who received TNFα MAb and 398 (42•8%) of 930 who received placebo had died at 28 days (95% CI −0•02 to 0•07, p=0•27). We found no association between therapy with TNFα MAb and increased rapidity in reversal of initial shock or prevention of subsequent shock. Similarly, baseline plasma interleukin-6 concentrations of more than 1000 pg/mL or detectable circulating TNF concentrations were not associated with improvement in survival after TNFα MAb therapy. Coagulopathy but not other organ or system failures, was significantly decreased in the TNFα MAb group compared with placebo (day 7, p<0•001; day 28, p=0•005). Serious adverse events were reported in 55•2% of patients given placebo and 54•1% in the TNFα MAb group. Interpretation We did not find an improvement in survival after septic shock with TNFα MAb. Therapy not solely dependent on TNFα blockade may be required to improve survival.